Community

Mahesh Karande

President and Chief Executive Officer, Omega Therapeutics

Mahesh Karande is deeply experienced in running biopharma businesses across discovery, preclinical development, clinical development, commercialization, and product life cycle management stages. His breadth of therapeutic experience spans cardiovascular and metabolic, oncology, neurosciences, ophthalmology, antibiotics, pain, respiratory, and rare and genetic diseases, as well as drug and device combinations. He has been involved with more than 10 product launches in the United States and across global markets. He has strong leadership, operational, and business-building experiences, combined with a global work history spanning the U.S., Europe, Asia, and Africa. Prior to taking the helm at Omega, Mr. Karande was President and CEO of Macrolide Pharmaceuticals, a company he took from discovery into early development. Earlier, Mr. Karande spent several years at Novartis in senior leadership roles: VP and Head of U.S. Oncology for solid tumors, President of Novartis Africa, and President of Novartis Egypt. He worked for McKinsey & Company prior to joining the biopharmaceutical industry. Mr. Karande has an MBA from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology, where he completed his MS in engineering, and the University of Bombay, where he completed his undergraduate studies.

Community

Mahesh Karande

President and Chief Executive Officer, Omega Therapeutics

Contributions

Q: What’s the key to being a leader in the industry?

Q: What important company milestone do you anticipate reaching in 2022?